Stéphane Bogen

Discovery of (1 <i>R</i> ,5 <i>S</i> )- <i>N</i> -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( <i>S</i> )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( <i>S</i> )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor:  A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Srikanth Venkatraman, Stéphane Bogen, Ashok Arasappan et al. · Journal of Medicinal Chemistry · 2006 · 282 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Characterization of resistance mutations against HCV ketoamide protease inhibitors

Xinchun Tong, Stéphane Bogen, Robert A. Chase et al. · Antiviral Research · 2008 · 127 citations

Life Sciences, Infectious Diseases, Molecular Biology +14

Discovery of the HCV NS3/4A Protease Inhibitor (1<i>R</i>,5<i>S</i>)-<i>N</i>-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(<i>S</i>)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(<i>S</i>)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization

Andrew Prongay, Zhuyan Guo, Nanhua Yao et al. · Journal of Medicinal Chemistry · 2007 · 108 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +13

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

MinKyung Yi, Xiao Tong, Angela Skelton et al. · Journal of Biological Chemistry · 2005 · 104 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor

Ashok Arasappan, Frank Bennett, Stéphane Bogen et al. · ACS Medicinal Chemistry Letters · 2010 · 98 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15